#NICE publishes final guidance recommending ataluren for children with #Duchenne muscular dystrophy | News and features | News | NICE

Originally posted 2016-07-20 15:12:34.

Today’s guidance follows the announcement on 7 July that NHS England and the company, PTC Therapeutics, have successfully negotiated a ‘managed access agreement’ that established financial and clinical details surrounding the use of ataluren.This ‘managed access agreement’ was a condition for making the drug available imposed by NICE in its April draft guidance.

Esta entrada fue publicada en Sin categoría. Guarda el enlace permanente.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *